Abstract: A fiber reinforced actuator includes first and second sets of fibers coupled with and arranged along a control volume to controllably constrain mobility of an actuator body. Fibers of the first set can be arranged with respect to fibers of the second set and with respect to a central axis to impart the actuator with various combinations of torsional and axial force responses. A third fiber may be included to form a helical actuator. A plurality of actuators can be coupled together for coordinated movement, thereby providing additional mobility directions, such as trans-actuator bending. The fiber-reinforced actuators and actuator assemblies are potential low cost, low energy consumption, lightweight, and simple replacements for existing motion devices such as servo-motor driven robots.

Abstract: The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.

Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.

Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.